Daxor (DXR) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Daxor (DXR) has outperformed Stereotaxis (STXS) over the past year, losing 20.0% versus a loss of 68.9%. Over five years, DXR leads with a -7.0% price change compared with -81.3% for STXS. Stereotaxis is the larger company by market cap ($110.2 million vs $61.2 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | STXS |
|---|---|---|
| Share price | $10.49 | $1.10 |
| Market cap | $61.21M | $110.22M |
| 1-day change | +0.24% | -0.90% |
| YTD return | -29.08% | -51.74% |
| 1-year return | -20.03% | -68.91% |
| 5-year return | -7.02% | -81.28% |
| P/E ratio (TTM) | 9.53 | — |
| EPS (TTM) | $1.10 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.76 | $3.42 |
| 52-week low | $8.56 | $1.09 |
| Distance from 52-week high | -28.96% | -67.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +90.75% | +172.73% |
| Average volume | 17.27K | 808.41K |
| Shares outstanding | 5.84M | 100.20M |
| Employees | — | 131 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXR has outperformed STXS by 48.9 percentage points over the past year.
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
DXR vs STXS FAQ
Which is bigger, Daxor or Stereotaxis?
Stereotaxis (STXS) is larger, with a market capitalization of $110.22M compared with $61.21M for Daxor (DXR).
Which stock has performed better over the past year, DXR or STXS?
DXR returned -20.03% over the past 12 months, compared with -68.91% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are Daxor and Stereotaxis in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Daxor and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Stereotaxis.